Loss-of-function mutations in the SOST gene are associated with high bone mass [43], and the sclerostin antibody Romosozumab is a recently approved drug for the therapy of postmenopausal osteoporosis [44]. This evidence concerns the gene SOST and postmenopausal osteoporosis.